Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhaseDiscontinued |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase II Trial of TBL12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
This study proposes to determine the clinical activity of this agent in patients with asymptomatic multiple myeloma. It is believed that TBL12 will help delay the onset of active multiple myeloma, with very few-if any- side effects.
A Phase II Trial of TBL 12 Sea Cucumber Extract in Patients With Untreated Asymptomatic Myeloma
Purpose:
The purpose of this study is to see if TBL 12, which is a blend of Sea Cucumber, Sea Sponge, Shark Fin, and Sea Urchin (animals that live in the Pacific Ocean) as well as Sargassum (a plant that lives in the Pacific Ocean), will have effects against asymptomatic multiple myeloma and to see what the side effects are.
Eligibility:
Several criteria must be met to be eligible for this study, including but not limited to the following:
a diagnosis of asymptomatic multiple myeloma
adequate cardiac, liver and kidney function
age 18 and older
100 Clinical Results associated with Unicorn Pacific Corp.
0 Patents (Medical) associated with Unicorn Pacific Corp.
100 Deals associated with Unicorn Pacific Corp.
100 Translational Medicine associated with Unicorn Pacific Corp.